Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - sondelbay is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - disturbi fl-emigranja - analġeżiċi - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obeżità - preparazzjonijiet ta 'kontra l-ossessjoni, esklużi prodotti tad-dieta - bħala żieda mad-dieta u l-eżerċizzju fil-kura tal-pazjenti bi ħxuna żejda (bmi 30 kg/m2), jew ta'pazjenti b'piż eċċessiv (bmi 27 kg/m2) bl-riskju assoċjat fattur(i), bħalma huma dijabete tip 2 jew dislipidemija (ara sezzjoni 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group hf - telmisartan, hydrochlorothiazide - essential hypertension - agents acting on the renin-angiotensin system, angiotensin ii antagonists and diuretics - trattament ta 'ipertensjoni essenzjali. actelsar hct kombinazzjoni b'doża fissa (40 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 25 mg hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata adegwatament fuq actelsar hct 80 mg / 12. 5 mg (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) jew adulti li qabel kienu stabbilizzati fuq telmisartan u hydrochlorothiazide mogħtija separatament.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - febuxostat - gotta - preparazzjonijiet antigout - 80 mg saħħa:it-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat fl-adulti. 120 mg saħħa:adenuric huwa indikat għat-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat għall-prevenzjoni u t-trattament ta'l-iperuriċemija f'pazjenti adulti li għaddejjin minn kimoterapija għal tumuri malinni ematoloġiċi fil-intermedjarju u għoli tar-riskju tas-sindrome tal-lisi tat-tumur (tls). adenuric huwa indikat fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). advate ma fihx il-fattur von willebrand fi kwantitajiet farmakoloġiċi effettivi u għaldaqstant mhuwiex indikat fil-mard ta ' von willebrand.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - rasagiline - marda ta 'parkinson - mediċini kontra l-parkinson - azilect huwa indikat għat-trattament tal-marda idjopatika ta 'parkinson (pd), bħala monoterapija (mingħajr levodopa) jew bħala terapija miżjuda (ma' levodopa) f'pazjenti b'-tmiem tal-doża varjazzjonijiet.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - nonacog alfa - hemofilja b - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (nuqqas konġenitali ta' fattur ix).